The global Point of Care Lipid Test Marketstudy analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Instrument (Roche Reflotron, Roche Cobas b 101, Abaxis Piccolo, Alere Cholestech LDX, Alere Afinion, Samsung LABGEO, PTS Cardiochek), By Consumables (Roche Reflotron, Roche Cobas b 101, Abaxis Piccolo, Alere Cholestech LDX, Alere Afinion, Samsung LABGEO, PTS Cardiochek), By Application (Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier disease, Others).
Assessing lipid levels for cardiovascular risk assessment, the Point of Care Lipid Test Market offers rapid and convenient tests for measuring cholesterol and lipid profiles at the point of care, such as physician offices, clinics, pharmacies, and community health centers. Point-of-care lipid testing devices provide quick results for total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides, helping clinicians evaluate lipid status and guide treatment decisions for cardiovascular disease prevention. The market's growth is driven by the increasing emphasis on preventive healthcare, the need for early detection and management of dyslipidemia, and the availability of portable and easy-to-use lipid testing devices facilitating timely intervention and risk stratification.
The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments across Abbott Laboratories, F. Hoffmann-La Roche Ltd, Menarini Group, Mico Bio Med, Nova Biomedical Corp, SD Biosensor Inc, Sinocare Inc, VivaChek Biotech Co. Ltd, Zoetis Inc, and Others.
A significant trend in the Point of Care Lipid Test market is the growing emphasis on preventive healthcare and cardiovascular disease management. With rising awareness of the importance of cholesterol monitoring in preventing heart disease and stroke, there is a growing demand for convenient and accessible lipid testing solutions at the point of care. This trend is driving the adoption of Point of Care Lipid Tests by healthcare providers and patients alike, leading to market growth and innovation in lipid testing technologies.
A key driver in the Point of Care Lipid Test market is the escalating burden of cardiovascular diseases globally. Cardiovascular diseases, including coronary artery disease, stroke, and peripheral artery disease, are leading causes of morbidity and mortality worldwide, with elevated cholesterol levels being a major risk factor. Healthcare providers rely on lipid testing to assess cardiovascular risk, guide treatment decisions, and monitor lipid-lowering therapies, driving demand for Point of Care Lipid Tests to facilitate timely diagnosis and management of lipid disorders.
An enticing opportunity in the Point of Care Lipid Test market lies in the expansion into retail and community settings to improve access to lipid testing services. Retail pharmacies, clinics, and community health centers serve as convenient locations for individuals to undergo lipid testing outside of traditional healthcare settings. By partnering with retail chains and community organizations, Point of Care Lipid Test manufacturers can reach a broader population, increase awareness of lipid health, and provide accessible testing solutions to individuals at risk of cardiovascular disease, thereby expanding their market reach and driving revenue growth.
The Point of Care (PoC) Lipid Test market is poised for significant growth, with the Alere Cholestech LDX instrument projected to dominate in revenue generation by 2025. This system's widespread adoption stems from its ability to deliver rapid, reliable lipid panel results in various healthcare settings such as clinics, pharmacies, and mobile screening programs. Its compact design, minimal training requirement, and integration with electronic health records (EHRs) make it especially suitable for decentralized care models and preventive health initiatives. The rising prevalence of cardiovascular diseases and metabolic disorders has driven demand for real-time lipid monitoring, and the Alere Cholestech LDX's proven track record for clinical accuracy has strengthened its position as the preferred choice among healthcare providers. Furthermore, its CLIA-waived status in the U.S. adds to its regulatory appeal, enabling broader deployment in point-of-care environments. Although competitors such as Roche Cobas b 101 and Samsung LABGEO are gaining traction due to technological advancements, they face limitations in terms of operational ease, test menu variety, or cost-efficiency in low-resource settings. The growing global focus on early risk detection and personalized treatment for lipid disorders continues to fuel the demand for portable, fast, and user-friendly testing platforms, giving Alere Cholestech LDX a notable competitive edge.
The hyperlipidemia segment is poised to be the fastest-growing application in the point of care lipid test market through 2034, driven by the global surge in cardiovascular disease prevalence and the urgent need for early, decentralized diagnosis. With sedentary lifestyles, obesity, and poor dietary habits contributing to rising cholesterol levels worldwide, healthcare providers are increasingly relying on rapid lipid testing solutions to screen and monitor patients outside of conventional lab settings. Hyperlipidemia, being the most common lipid disorder, creates a high-volume testing requirement that aligns with the strengths of point-of-care diagnostics—speed, portability, and convenience. Moreover, expanding access to healthcare in rural areas, along with government initiatives promoting cardiovascular risk screening, particularly in aging populations, is reinforcing this segment’s dominant trajectory.
By Instrument
By Consumables
By Application
Geographical Analysis
*List not Exhaustive
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Point of Care Lipid Test Market, encompassing current market size, growth trends, and forecasts till 2034.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Point of Care Lipid Test Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2025 Point of Care Lipid Test Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Point of Care Lipid Test Market Size Outlook, $ Million, 2021 to 2034
3.2 Point of Care Lipid Test Market Outlook by Type, $ Million, 2021 to 2034
3.3 Point of Care Lipid Test Market Outlook by Product, $ Million, 2021 to 2034
3.4 Point of Care Lipid Test Market Outlook by Application, $ Million, 2021 to 2034
3.5 Point of Care Lipid Test Market Outlook by Key Countries, $ Million, 2021 to 2034
4 Market Dynamics
4.1 Key Driving Forces of Point of Care Lipid Test Industry
4.2 Key Market Trends in Point of Care Lipid Test Industry
4.3 Potential Opportunities in Point of Care Lipid Test Industry
4.4 Key Challenges in Point of Care Lipid Test Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Point of Care Lipid Test Market Share by Company (%), 2025
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Point of Care Lipid Test Market Outlook by Segments
7.1 Point of Care Lipid Test Market Outlook by Segments, $ Million, 2021- 2034
By Instrument
Roche Reflotron
Roche Cobas b 101
Abaxis Piccolo
Alere Cholestech LDX
Alere Afinion
Samsung LABGEO
PTS Cardiochek
By Consumables
Roche Reflotron
Roche Cobas b 101
Abaxis Piccolo
Alere Cholestech LDX
Alere Afinion
Samsung LABGEO
PTS Cardiochek
By Application
Hyperlipidemia
Hypertriglyceridemia
Familial Hypercholesterolemia
Hyperlipoproteinemia
Tangier disease
Others
8 North America Point of Care Lipid Test Market Analysis and Outlook To 2034
8.1 Introduction to North America Point of Care Lipid Test Markets in 2024
8.2 North America Point of Care Lipid Test Market Size Outlook by Country, 2021-2034
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Point of Care Lipid Test Market size Outlook by Segments, 2021-2034
By Instrument
Roche Reflotron
Roche Cobas b 101
Abaxis Piccolo
Alere Cholestech LDX
Alere Afinion
Samsung LABGEO
PTS Cardiochek
By Consumables
Roche Reflotron
Roche Cobas b 101
Abaxis Piccolo
Alere Cholestech LDX
Alere Afinion
Samsung LABGEO
PTS Cardiochek
By Application
Hyperlipidemia
Hypertriglyceridemia
Familial Hypercholesterolemia
Hyperlipoproteinemia
Tangier disease
Others
9 Europe Point of Care Lipid Test Market Analysis and Outlook To 2034
9.1 Introduction to Europe Point of Care Lipid Test Markets in 2024
9.2 Europe Point of Care Lipid Test Market Size Outlook by Country, 2021-2034
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Point of Care Lipid Test Market Size Outlook by Segments, 2021-2034
By Instrument
Roche Reflotron
Roche Cobas b 101
Abaxis Piccolo
Alere Cholestech LDX
Alere Afinion
Samsung LABGEO
PTS Cardiochek
By Consumables
Roche Reflotron
Roche Cobas b 101
Abaxis Piccolo
Alere Cholestech LDX
Alere Afinion
Samsung LABGEO
PTS Cardiochek
By Application
Hyperlipidemia
Hypertriglyceridemia
Familial Hypercholesterolemia
Hyperlipoproteinemia
Tangier disease
Others
10 Asia Pacific Point of Care Lipid Test Market Analysis and Outlook To 2034
10.1 Introduction to Asia Pacific Point of Care Lipid Test Markets in 2024
10.2 Asia Pacific Point of Care Lipid Test Market Size Outlook by Country, 2021-2034
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Point of Care Lipid Test Market size Outlook by Segments, 2021-2034
By Instrument
Roche Reflotron
Roche Cobas b 101
Abaxis Piccolo
Alere Cholestech LDX
Alere Afinion
Samsung LABGEO
PTS Cardiochek
By Consumables
Roche Reflotron
Roche Cobas b 101
Abaxis Piccolo
Alere Cholestech LDX
Alere Afinion
Samsung LABGEO
PTS Cardiochek
By Application
Hyperlipidemia
Hypertriglyceridemia
Familial Hypercholesterolemia
Hyperlipoproteinemia
Tangier disease
Others
11 South America Point of Care Lipid Test Market Analysis and Outlook To 2034
11.1 Introduction to South America Point of Care Lipid Test Markets in 2024
11.2 South America Point of Care Lipid Test Market Size Outlook by Country, 2021-2034
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Point of Care Lipid Test Market size Outlook by Segments, 2021-2034
By Instrument
Roche Reflotron
Roche Cobas b 101
Abaxis Piccolo
Alere Cholestech LDX
Alere Afinion
Samsung LABGEO
PTS Cardiochek
By Consumables
Roche Reflotron
Roche Cobas b 101
Abaxis Piccolo
Alere Cholestech LDX
Alere Afinion
Samsung LABGEO
PTS Cardiochek
By Application
Hyperlipidemia
Hypertriglyceridemia
Familial Hypercholesterolemia
Hyperlipoproteinemia
Tangier disease
Others
12 Middle East and Africa Point of Care Lipid Test Market Analysis and Outlook To 2034
12.1 Introduction to Middle East and Africa Point of Care Lipid Test Markets in 2024
12.2 Middle East and Africa Point of Care Lipid Test Market Size Outlook by Country, 2021-2034
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Point of Care Lipid Test Market size Outlook by Segments, 2021-2034
By Instrument
Roche Reflotron
Roche Cobas b 101
Abaxis Piccolo
Alere Cholestech LDX
Alere Afinion
Samsung LABGEO
PTS Cardiochek
By Consumables
Roche Reflotron
Roche Cobas b 101
Abaxis Piccolo
Alere Cholestech LDX
Alere Afinion
Samsung LABGEO
PTS Cardiochek
By Application
Hyperlipidemia
Hypertriglyceridemia
Familial Hypercholesterolemia
Hyperlipoproteinemia
Tangier disease
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott Laboratories
F. Hoffmann-La Roche Ltd
Menarini Group
Mico Bio Med
Nova Biomedical Corp
SD Biosensor Inc
Sinocare Inc
VivaChek Biotech Co. Ltd
Zoetis Inc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Instrument
By Consumables
By Application
Geographical Analysis
The Global Point Of Care Lipid Test Market Size is estimated at $912.1 Million in 2025 and is forecast to register an annual growth rate (CAGR) of 6.7% to reach $1635 Million by 2034.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Abbott Laboratories, F. Hoffmann-La Roche Ltd, Menarini Group, Mico Bio Med, Nova Biomedical Corp, SD Biosensor Inc, Sinocare Inc, VivaChek Biotech Co. Ltd, Zoetis Inc
Base Year- 2024; Estimated Year- 2025; Historic Period- 2019-2024; Forecast period- 2025 to 2034; Currency: Revenue (USD); Volume